About intensity therapeutics inc - INTS
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.
INTS At a Glance
Intensity Therapeutics, Inc.
1 Enterprise Drive
Shelton, Connecticut 06484-4779
| Phone | 1-203-221-7381 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -11,606,000.00 | |
| Sector | Health Technology | Employees | 16 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
INTS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.18 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.176 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.052 |
INTS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -725,375.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
INTS Liquidity
| Current Ratio | 5.922 |
| Quick Ratio | 5.922 |
| Cash Ratio | 5.555 |
INTS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -122.75 |
| Return on Equity | -156.901 |
| Return on Total Capital | -96.83 |
| Return on Invested Capital | -154.922 |
INTS Capital Structure
| Total Debt to Total Equity | 0.926 |
| Total Debt to Total Capital | 0.918 |
| Total Debt to Total Assets | 0.779 |
| Long-Term Debt to Equity | 0.665 |
| Long-Term Debt to Total Capital | 0.659 |